AKR1C3 and cancer: Surprisingly, chalcone 25, a weak AKR1C3 inhibitor that could not be docked into the binding pocket of AKR1C3, had cytotoxic effects in almost the same concentration range as chemotherapeutic agents cisplatin and etoposide, conventionally used in cancer treatment.